| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00301366 | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency | PHASE3 | COMPLETED | 38 | — | — | Jun 1, 2006 | Mar 1, 2007 | Aug 19, 2014 | 10 | United States, United Kingdom |
| NCT00263887 | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) | PHASE2 | COMPLETED | 77 | — | — | Dec 1, 2003 | Jan 1, 2007 | Aug 21, 2014 | 3 | Denmark, Sweden +1 |
An adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product. The adverse event does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the medicinal product.
| Arm | Type | Description |
|---|---|---|
| Alpha-1 Proteinase Inhibitor (Human), modified process | EXPERIMENTAL | Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects. |
| Group 1 | EXPERIMENTAL | Prolastin |
| Group 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| alpha-1 proteinase inhibitor (human) | DRUG | 60 mg/kg weekly for 20 weeks |
| Alpha1-Proteinase Inhibitor (Human) | DRUG | Weekly infusion of 60 mg/kg body weight for 2 years |
| Albumin (Human) 20%, United States Pharmacopeia (USP) | DRUG | Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%. |
Inclusion Criteria: * Documented diagnosis of congenital Alpha1-antitrypsin deficiency * Documented forced expiratory volume in 1 second (FEV1 ) between 20% - 80% of predicted value within last 6 months. * Signed written informed consent prior to initiation of any study related procedures. Exclusi...